L. Evan Michael, MD, PhD, FAAD

Physician, Board Certified in Dermatology and Dermatopathology

Professional

Dermatology of North Asheville, Asheville, NC

Dermatologist, 2/2020 to present

Dermatology Institute for Skin Cancer & Cosmetic Surgery, Newnan, GA

Dermatologist and Dermatopathologist, 5/2018-1/2020

Atlanta Dermatopathology, Atlanta, GA

Dermatopathologist and Laboratory Technical Director, 8/2015-4/2018

Education and Training

Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College of Cornell University, New York, NY

Dermatopathology fellowship, 7/2014-6/2015

University of Alabama at Birmingham Department of Dermatology, Birmingham, AL

Dermatology residency, 7/2011-6/2014

Memorial Sloan-Kettering Cancer Center, New York, NY

Transitional Year medical internship, 7/2010-6/2011

University of Michigan Medical School and Rackham Graduate School, Ann Arbor, MI

MD with Distinction in Research, 5/2010 PhD in Cellular and Molecular Biology, 5/2010

National Cancer Institute, National Institutes of Health, Bethesda, MD

Pre-Doctoral Cancer Research Training Associate fellowship, Laboratory of Cellular Carcinogenesis and Tumor Promotion; Stuart H. Yuspa, MD, lab chief 7/1999-6/2001

Grinnell College, Grinnell, IA

BA, Biology, 6/1999

Board Certifications

Dermatology, American Board of Dermatology, 7/2014 Dermatopathology, American Board of Dermatology, 9/2015

Medical licenses and Professional Society and Interest Group Memberships

State of Georgia Medical License #74221

State of North Carolina Medical License #209044

American Academy of Dermatology, Fellow

American Society of Dermatopathology

American Medical Association

Atlanta Association for Dermatology and Dermatologic Surgery

Georgia Society of Dermatology and Dermatologic Surgery

Honors and Awards

University of Michigan

Department of Dermatology Arthur C. Curtis Award for Excellence in Dermatology Basic Science, 2010

Dean's Commendation for Excellence in Clinical Skills and the Art of Medicine, 2009 Alpha Omega Alpha Honor Medical Society, elected 2009

Albert Kligman Travel Award Fellowship, The Society for Investigative Dermatology, 2008 First place abstract selection, Comprehensive Cancer Center Fall Research Symposium, 2007

Bibliography

- 1. Smith CM, Diehl J, **Michael LE**, Kent D. Eruptive Porokeratosis in an 80-year-old immunocompetent man. Our Dermatol Online. 2018;9(2):220-222.
- 2. Xu T, Zhang H, Park S, Venneti S, Kuick R, Ha K, **Michael LE**, Uchida C, Uchida T, Dlugosz AA, Camelo-Piragua, S, Rual J. PIN1 protects GLI1 from ubiquitination and promotes Hedgehog-driven medulloblastoma tumorigenesis. *Neoplasia*, 19(3): 216-225, 2017
- 3. Grachtchouk M, Pero J, Yang SH, Ermilov AN, **Michael LE**, Wang A, Wilbert D, Patel RM, Ferris J, Diener J, Allen M, Lim S, Syu LJ, Verhaegen M, Dlugosz AA. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. *J Clin Invest* 2011 May;121(5):1768-81
- 4. Cheng X, Jin J, Hu L, Shen D, Dong XP, Samie MA, Knoff J, Eisinger B, Liu ML, Huang SM, Caterina MJ, Dempsey P, **Michael LE**, Dlugosz AA, Andrews NC, Clapham DE, Xu H. TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. *Cell* 2010 Apr 16;141(2):331-43
- Michael LE, Westerman BA, Ermilov AN, Wang A, Ferris J, Liu J, Blom M, Ellison DW, van Lohuizen M, Dlugosz AA. Bmi1 is Required for Hedgehog Pathway-Driven Medulloblastoma Expansion. Neoplasia 10(12):1343-1349, 2008. Cover article
- 6. Rittié L, Kansra S, Stoll SW, Li Y, Gudjonsson JE, Shao Y, **Michael LE**, Fisher GJ, Johnson TM, Elder JT. Differential ErbB1 Signaling in Squamous Cell versus Basal Cell Carcinoma of the Skin, *Am J Pathol* 170(6):2089-99, 2007
- 7. Hutchin ME, Kariapper MS, Grachtchouk M, Wang A, Wei L, Cummings D, Liu J, **Michael LE**, Glick A, Dlugosz AA. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle, *Genes Dev* 19(2):214-23, 2005
- 8. Woodworth CD, **Michael E**, Marker D, Allen S, Smith L, Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment, *Mol Cancer Ther* 4(4):650-8, 2005
- 9. Hyun TS, Rao DS, Saint-Dic D, **Michael LE**, Kumar PD, Bradley SV, Mizukami IF, Oravecz-Wilson KI, Ross TS. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains, *J Biol Chem* 279(14):14294-306, 2004
- 10. Woodworth CD, **Michael E**, Smith L, Vijayachandra K, Glick A, Hennings H, Yuspa SH. Strain-dependent differences in malignant conversion of mouse skin tumors is an inherent property of the epidermal keratinocyte, *Carcinogenesis* 25(9):1771-8, 2004
- 11. Woodworth CD, Gaiotti D, **Michael E**, Hansen L, Nees M. Targeted disruption of the epidermal growth factor receptor inhibits development of papillomas and carcinomas from human papillomavirus-immortalized keratinocytes, *Cancer Res* 60(16):4397-402, 2000